Render Target: SSR
Render Timestamp: 2024-11-14T22:57:36.024Z
Commit: 3c1f305a63297e594ac8d7bb5424007d592d68be
XML generation date: 2024-09-30 01:58:14.358
Product last modified at: 2024-09-30T08:00:22.599Z
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

Phospho-CD79A (Tyr210) (E8E9Z) Rabbit mAb #89660

Filter:
  • WB
  • F

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 50
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • F-Flow Cytometry 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Flow Cytometry (Fixed/Permeabilized) 1:400 - 1:1600

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    Phospho-CD79A (Tyr210) (E8E9Z) Rabbit mAb recognizes endogenous levels of CD79A protein only when phosphorylated at Tyr210.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr210 of human CD79A protein.

    Background

    Antigen receptors found on the surface of B cells contain a heterodimeric signaling component composed of CD79A and CD79B, also known as Ig α and Ig β, respectively (1,2). Presence of this receptor complex is essential for B cell development and function (3). Together these two proteins and the associated B cell receptor (BCR) initiate intracellular signaling following antigen binding (4,5). An immunoreceptor tyrosine-based activation motif (ITAM) found in the CD79A intracellular region appears to be important for its function (6). Antigen binding precedes formation of the CD79A and CD79B heterodimer and subsequent activation of receptor associated kinases (7). Research has shown that CD79A is a marker for B-lineage lymphoblastic leukemia (8). Additionally, investigators have found that mutations in the CD79A (MB1) gene are associated with abnormally low levels of functional B cell receptors in some cases of chronic B cell lymphocytic leukemia (9).
    Tyrosine 210 is an evolutionarily conserved non-ITAM tyrosine residue that lies within the cytoplasmic domain of CD79A/Ig-α. Research studies have shown that ligation of the BCR induces phosphorylation of tyrosine 210, which facilitates both the recruitment of BLNK to the BCR signaling complex and the activation of downstream Syk-dependent signaling (10,11). Collectively, these molecular events drive B cell activation and proliferation (12).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    Alexa Fluor is a registered trademark of Life Technologies Corporation.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.